Caris Life Sciences: Dave Fredrickson
Caris Life Sciences has appointed David Fredrickson to its board of directors. Fredrickson is executive VP of the oncology business unit at AstraZeneca, a position he has held since October of 2017. He was previously president of AstraZeneca Japan, and VP, specialty care of AstraZeneca US. He also previously served as vice chairman of the European Federation of Pharmaceutical Industries and Associations in Japan and director of the Japan Pharmaceutical Manufacturers Association. Prior to AstraZeneca, he held leadership positions at Roche/Genentech, including oncology business unit manager in Spain and strategy, marketing, and sales roles in the US. He has also worked at the Monitor Group (now Monitor Deloitte Group), a global strategy consultancy. Fredrickson earned a BA degree in government from Georgetown University.
Bio-Rad Laboratories: Jon DiVincenzo
Bio-Rad Laboratories has appointed Jon DiVincenzo as president and chief operating officer, effective Sept. 9. DiVincenzo will replace Andrew Last, who is retiring. DiVincenzo most recently served as executive VP and president of the central laboratory and international business at Laboratory Corporation of America. He also previously served as president of the environmental health division at PerkinElmer, as CEO of Enzymatics, and in various roles at EMD Millipore, a subsidiary of Merck.
Quanterix: Jeffrey Elliott
Quanterix said this week that it has appointed Jeffrey Elliott to its board of directors. Elliott was CFO at Exact Sciences from November 2016 to May 2024 and COO from April 2021 to May 2023. Prior to that he was a senior equity research analysts at Robert W. Baird & Co.
Broken String Biosciences: Steve Becker
Steve Becker has been appointed as chief commercial officer of Broken String Biosciences. He joins the Cambridge, UK-based genome technology company from Thermo Fisher Scientific, where he led the licensing and commercial supply channel for the genetic sciences and clinical oncology NGS divisions. Before that, he held executive positions at Quest Diagnostics, Athena Diagnostics, and RainDance Technologies, as well as leadership roles at Agilent Technologies and GE Healthcare.
Moonwalk Biosciences: John Liles, Paul Cohen, Silvia Corvera, Michael Czech, Shingo Kajimura, Rohit Loomba
John Liles has been appointed as VP of biology and translational science at Moonwalk Biosciences. He comes to the California epigenetics company from Chinook Therapeutics, where he was executive director of kidney disease research and strategy. Prior to that, he led research and pharmacology teams at Gilead Sciences. Liles holds a PhD in pharmacology from Tulane University.
Moonwalk has also formed a cardiometabolic advisory board. Members of the board are Paul Cohen, associate professor at Rockefeller University; Silvia Corvera, professor at UMass Chan Medical School; Michael Czech, professor at UMass Chan Medical School; Shingo Kajimura, professor at Harvard Medical School; and Rohit Loomba, director of the University of California San Diego MASLD Research Center.
Noscendo: James Rothman
James Rothman has joined the board of directors of German sequencing-based infectious disease diagnostics firm Noscendo as an independent director. He is a professor of cell biology at Yale University and a 2013 Nobel laureate.
Centogene: Thomas Wiedermann
Thomas Wiedermann has been appointed as chief restructuring officer and a managing director of Centogene. He will oversee measures to improve the firm's cost savings and liquidity and will be able to make decisions without consent from any other managing directors. His initial term expires May 31, 2025, unless it is terminated earlier. Wiedermann will also operate as a de facto member of Centogene's management board and has power of attorney to act on behalf of the company.
For additional recent items on executive appointments, promotions, and departures in the omics and molecular diagnostics space, please see the People in the News page on our website.